Effect of generic-only drug benefits on seniors' medication use and financial burden

American Journal of Managed Care

Volumn 12, Issue 9, 2006, Pages 525-532

  Tseng, Chien Wen ^a,b,c   Brook, Robert H ^c,d,e   Keeler, Emmett ^e   Steers, W Neil ^d   Waitzfelder, Beth E ^b   Mangione, Carol M ^c,d,e  

^a UNIVERSITY OF HAWAII   (United States)

^b PACIFIC HEALTH RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e RAND CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALAT CC; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ANTITHROMBOCYTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DIGOXIN; DILTIAZEM; FLUOXETINE; GENERIC DRUG; HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEVOTHYROXINE SODIUM; NIFEDIPINE; PAROXETINE; PROTON PUMP INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; WARFARIN;

AGED; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; ELDERLY CARE; FEMALE; FINANCIAL MANAGEMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MEDICARE; MULTIVARIATE ANALYSIS; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; TREATMENT WITHDRAWAL;

AGED; COST OF ILLNESS; CROSS-SECTIONAL STUDIES; DRUGS, GENERIC; FEMALE; FINANCING, PERSONAL; HUMANS; INSURANCE COVERAGE; INSURANCE, HEALTH; MALE; UNITED STATES;

EID: 33748856050     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Commonwealth Fund. Medicare+Choice plans continue to shift more costs to enrollees. April 2003. Available at: http://www.cmwf.org/publications/ publications:_ show.htm?doc._d=221336. Accessed August 7, 2006.
2. American Association of Retired Persons. Public Policy Institute issue brief: generic drugs. May 2003. Available at: http://assets.aarp.org/rgcenter/ health/ib61_generic.pdf. Accessed August 7, 2006.
3. Fischer MA, Avorn J. Economic consequences of underuse of generic drugs: evidence from Medicaid and implications for prescription drug benefit plans. Health Serv Res. 2003;38:1051-1063.
4. Fischer MA, Avorn J. Potential savings from increased use of generic drugs in the elderly: what the experience of Medicaid and other insurance programs means for a Medicare drug benefit. Pharmacoepidemiol Drug Saf. 2004;13:207-214.
5. Christian-Herman J, Emons M, George D. Effects of generic-only drug coverage in a Medicare HMO. Health Aff (Millwood). July-December 2004;suppl Web exclusive W4:455-468.
6. Ritter G, Thomas CP, Wallack SS. Greater Use of Generics: A Prescription for Drug Cost Savings. Waltham, Mass: Schneider Institute for Health Policy, Heller School, Brandeis University; February 2002.
7. Haas JS, Phillips KA, Gerstenberger EP, Seger AC. Potential savings from substituting generic drugs for brand name drugs: Medical Expenditure Panel Survey, 1997-2000. Ann Intern Med. 2005;142:891-897.
8. Medicare Web site. Landscape of local plans state-by-state breakdown. Available at: http://www.medicare.gov/medicarereform/map.asp. Accessed August 7, 2006.
9. Henry J. Kaiser Family Foundation. Medicare fact sheet: the Medicare prescription drug benefit. June 2006. Available at: http://www.kff.org/medicare/ upload/7044-04.pdf. Accessed August 7, 2006.
10. Stuart B, Briesacher BA, Shea OC, Cooper B, Bay sac FS, Limcangco MR. Riding the rollercoaster: the ups and downs in out-of-pocket spending under the standard Medicare drug benefit [published correction appears in Health Aff (Millwood). 2005;24:1380]. Health Aff (Millwood). 2005;24:1022-1031.
11. Tseng C, Brook RH, Keeler E, Steers WN, Mangione CM. Cost-lowering strategies by Medicare beneficiaries who exceed drug benefit caps and have a gap in drug coverage. JAMA. 2004;292:952-960.
12. STATA [computer program]. Release 8.2, College Station, Tex: StataCorp LP; 2004.
13. Oregon Health & Science University Web site. Drug class review on angiotensin converting enzyme inhibitors: final report. June 2005. Available at: http://www.oregon.gov/DAS/OHPPR/HROdocs/ACE_EPC.pdf. Accessed August 7, 2006.
14. Treatment guidelines for peptic ulcer. Med Lett Drugs Ther. 2004;2:9-12.
15. OTC loratadine. Med Lett Drugs Ther. 2003;45:3-4.
16. Schneeweiss S, Walker AM, Glynn RJ, Maclure M, Dormuth C, Soumerai SB. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. N Engl J Med. 2002;346:822-829.
17. Schneeweiss S, Soumerai SB, Maclure M, Dormuth C, Walker AM, Glynn RJ. Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers. Clin Pharmacol Ther. 2003;74:388-400.
18. Drugs for lipids: treatment guidelines from The Medical Letter. Med Lett Drugs Ther. 2005;3:15-22.
19. Banahan BF III, Kolassa EM. A physician survey on generic drugs and substitution of critical dose medications. Arch Intern Med. 1997;157:2080-2088.
20. Mott DA, Cline RR. Exploring generic drug use behavior: the role of prescribers and pharmacists in the opportunity for generic drug use and generic substitution. Med Care. 2002;40:662-674.
21. American Association of Retired Persons. Prescription medication use among persons age 45+. 2002. Available at: http://www.kaisernetwork.org/ health_cost/uploaded_files/AARP_Slides.pdf. Accessed August 7, 2006.
22. Bower AD, Burket GL. Family physicians and generic drugs: a study of recognition, information sources, prescribing attitudes, and practices. J Fam Pract. 1987;24:602-606.
23. American Association of Retired Persons. Physicians' attitudes and practices regarding generic drugs. March 2005. Available at: http://assets.aarp.org/rgcenter/health/phys_generic.pdf. Accessed August 7, 2006.
24. Joyce GF, Escarce JJ, Solomon MD, Goldman DP. Employer drug benefit plans and spending on prescription drugs. JAMA. 2002;288:1733-1739.
25. Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Frank RG. The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med. 2003;349:2224-2232.